Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
30
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Raman Prakash | Director | 15 | $0 | $0 | 2026-09-18 |
| Behbahani Ali | Director | 36 | $20.20M | $0 | 2026-09-18 |
| Campbell Shannon | Director | 7 | $0 | $0 | 2026-06-26 |
| Kulkarni Samarth | Director | 7 | $0 | $0 | 2026-06-26 |
| Menzel Garry E | Director | 9 | $0 | $0 | 2026-06-26 |
| Dhingra Kapil | Director | 7 | $0 | $0 | 2026-06-26 |
| Jones Erika | SEE REMARKS | 8 | $0 | $0 | 2026-01-21 |
| Buck Elizabeth | CHIEF SCIENTIFIC OFFICER | 6 | $0 | $0 | 2026-01-21 |
| Velleca Mark A. | PRESIDENT & CEO | 15 | $0 | $0 | 2026-01-21 |
| Yurasov Sergey | CHIEF MEDICAL OFFICER | 5 | $0 | $0 | 2026-01-21 |
| Hatzis-Schoch Brent | See Remarks | 53 | $57.0K | $1.37M | 2026-01-21 |
| BIOTECH GROWTH N V | 10% Owner | 16 | $13.63M | $12.00M | 2025-03-19 |
| Versant Voyageurs I Parallel, L.P. | 10% Owner | 69 | $0 | $4.22M | 2024-08-28 |
| DIXON WENDY L | Director | 12 | $0 | $0 | 2024-03-15 |
| Ni Fang | SEE REMARKS | 6 | $133.3K | $0 | 2024-02-14 |
| RA CAPITAL MANAGEMENT, L.P. | Director | 1 | $4.68M | $0 | 2023-07-05 |
| BB BIOTECH AG | 10% Owner | 6 | $6.05M | $0 | 2023-06-30 |
| Epstein David M. | See Remarks | 28 | $0 | $1.67M | 2023-06-27 |
| Mayweg Alexander | Director | 3 | $0 | $0 | 2023-05-16 |
| Shah Rajeev M. | Director | 21 | $19.00M | $0 | 2023-05-16 |
| INGRAM ROBERT ALEXANDER | Other | 13 | $152.3K | $0 | 2022-12-16 |
| Bolzon Bradley J PhD | Director, 10% Owner | 193 | $17.00M | $11.67M | 2021-06-18 |
| Roberts Christopher D. | Chief Scientific Officer | 38 | $0 | $825.2K | 2021-05-03 |
| Leggett Thomas | Chief Financial Officer | 18 | $0 | $495.6K | 2021-02-17 |
| HUMPHREY RACHEL | Chief Medical Officer | 3 | $0 | $0 | 2021-02-17 |
| Versant Vantage I, L.P. | 10% Owner | 19 | $0 | $5.95M | 2020-12-14 |
| Versant Voyageurs I, L.P. | 10% Owner | 34 | $0 | $831.0K | 2020-11-16 |
| Versant Venture Capital VI, L.P. | 10% Owner | 54 | $17.00M | $2.07M | 2020-11-12 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% Owner | 2 | $0 | $0 | 2020-02-03 |
| DEERFIELD PARTNERS, L.P. | 10% Owner | 3 | $7.60M | $0 | 2020-02-03 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Raman Prakash | Director | A Award | 2026-09-18 | 2026-09-21 | 6,801 | $1.93 | $13.1K | 51,840 | SEC↗ |
| Behbahani Ali | Director | A Award | 2026-09-18 | 2026-09-21 | 7,707 | $1.93 | $14.9K | 110,236 | SEC↗ |
| Raman Prakash | Director | A Award | 2026-09-18 | 2026-09-21 | 6,801 | $1.93 | $13.1K | 51,840 | SEC↗ |
| Behbahani Ali | Director | A Award | 2026-09-18 | 2026-09-21 | 7,707 | $1.93 | $14.9K | 110,236 | SEC↗ |
| Campbell Shannon | Director | A Award deriv | 2026-06-26 | 2026-06-29 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Dhingra Kapil | Director | A Award deriv | 2026-06-26 | 2026-06-29 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Raman Prakash | Director | A Award deriv | 2026-06-26 | 2026-06-29 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Menzel Garry E | Director | A Award deriv | 2026-06-26 | 2026-06-29 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Kulkarni Samarth | Director | A Award deriv | 2026-06-26 | 2026-06-29 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Behbahani Ali | Director | A Award deriv | 2026-06-26 | 2026-06-29 | 40,000 | — | $0 | 40,000 | SEC↗ |
| Raman Prakash | Director | A Award | 2026-06-19 | 2026-06-22 | 7,907 | $1.66 | $13.1K | 45,039 | SEC↗ |
| Behbahani Ali | Director | A Award | 2026-06-19 | 2026-06-22 | 8,961 | $1.66 | $14.9K | 102,529 | SEC↗ |
| Raman Prakash | Director | A Award | 2026-03-20 | 2026-03-20 | 6,105 | $2.15 | $13.1K | 37,132 | SEC↗ |
| Behbahani Ali | Director | A Award | 2026-03-20 | 2026-03-20 | 6,919 | $2.15 | $14.9K | 93,568 | SEC↗ |
| Velleca Mark A. | PRESIDENT & CEO | A Award deriv | 2026-01-21 | 2026-01-23 | 600,000 | — | $0 | 600,000 | SEC↗ |
| Yurasov Sergey | CHIEF MEDICAL OFFICER | A Award deriv | 2026-01-21 | 2026-01-23 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Buck Elizabeth | CHIEF SCIENTIFIC OFFICER | A Award deriv | 2026-01-21 | 2026-01-23 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Hatzis-Schoch Brent | SEE REMARKS | A Award deriv | 2026-01-21 | 2026-01-23 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Jones Erika | SEE REMARKS | A Award deriv | 2026-01-21 | 2026-01-23 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Raman Prakash | Director | A Award | 2025-12-12 | 2025-12-15 | 4,665 | $2.76 | $12.9K | 31,027 | SEC↗ |
| Behbahani Ali | Director | A Award | 2025-12-12 | 2025-12-15 | 5,208 | $2.76 | $14.4K | 86,649 | SEC↗ |
| Raman Prakash | Director | A Award | 2025-09-19 | 2025-09-22 | 3,843 | $3.35 | $12.9K | 26,362 | SEC↗ |
| Behbahani Ali | Director | A Award | 2025-09-19 | 2025-09-22 | 4,291 | $3.35 | $14.4K | 81,441 | SEC↗ |
| Raman Prakash | Director | A Award | 2025-06-20 | 2025-06-20 | 5,526 | $2.33 | $12.9K | 22,519 | SEC↗ |
| Behbahani Ali | Director | A Award | 2025-06-20 | 2025-06-20 | 6,170 | $2.33 | $14.4K | 77,150 | SEC↗ |
| Kulkarni Samarth | Director | A Award deriv | 2025-06-12 | 2025-06-12 | 30,550 | — | $0 | 30,550 | SEC↗ |
| Dhingra Kapil | Director | A Award deriv | 2025-06-12 | 2025-06-12 | 30,550 | — | $0 | 30,550 | SEC↗ |
| Campbell Shannon | Director | A Award deriv | 2025-06-12 | 2025-06-12 | 30,550 | — | $0 | 30,550 | SEC↗ |
| Raman Prakash | Director | A Award deriv | 2025-06-12 | 2025-06-12 | 30,550 | — | $0 | 30,550 | SEC↗ |
| Menzel Garry E | Director | A Award deriv | 2025-06-12 | 2025-06-12 | 30,550 | — | $0 | 30,550 | SEC↗ |
| Behbahani Ali | Director | A Award deriv | 2025-06-12 | 2025-06-12 | 30,550 | — | $0 | 30,550 | SEC↗ |
| Raman Prakash | Director | A Award | 2025-03-21 | 2025-03-21 | 6,848 | $1.88 | $12.9K | 16,993 | SEC↗ |
| Behbahani Ali | Director | A Award | 2025-03-21 | 2025-03-21 | 7,646 | $1.88 | $14.4K | 70,980 | SEC↗ |
| BIOTECH GROWTH N V | 10% Owner | S Sale | 2025-03-19 | 2025-03-20 | 584,292 | $1.95 | $1.14M | 3,233,547 | SEC↗ |
| BIOTECH GROWTH N V | 10% Owner | S Sale | 2025-03-19 | 2025-03-20 | 300,000 | $1.94 | $582.0K | 7,217,839 | SEC↗ |
| BIOTECH GROWTH N V | 10% Owner | S Sale | 2025-03-19 | 2025-03-20 | 1,000,000 | $2.31 | $2.31M | 6,217,839 | SEC↗ |
| BIOTECH GROWTH N V | 10% Owner | S Sale | 2025-03-19 | 2025-03-20 | 2,000,000 | $2.00 | $4.00M | 4,217,839 | SEC↗ |
| BIOTECH GROWTH N V | 10% Owner | S Sale | 2025-03-19 | 2025-03-20 | 1,000,000 | $2.07 | $2.07M | 7,517,839 | SEC↗ |
| BIOTECH GROWTH N V | 10% Owner | S Sale | 2025-03-19 | 2025-03-20 | 500,000 | $2.12 | $1.06M | 2,733,547 | SEC↗ |
| BIOTECH GROWTH N V | 10% Owner | S Sale | 2025-03-19 | 2025-03-20 | 400,000 | $2.09 | $836.0K | 3,817,839 | SEC↗ |
| Hatzis-Schoch Brent | SEE REMARKS | A Award deriv | 2025-01-30 | 2025-01-31 | 175,000 | — | $0 | 175,000 | SEC↗ |
| Jones Erika | SEE REMARKS | A Award deriv | 2025-01-30 | 2025-01-31 | 125,000 | — | $0 | 125,000 | SEC↗ |
| Buck Elizabeth | CHIEF SCIENTIFIC OFFICER | A Award deriv | 2025-01-30 | 2025-01-31 | 175,000 | — | $0 | 175,000 | SEC↗ |
| Yurasov Sergey | CHIEF MEDICAL OFFICER | A Award deriv | 2025-01-30 | 2025-01-31 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Velleca Mark A. | PRESIDENT & CEO | A Award deriv | 2025-01-30 | 2025-01-31 | 500,000 | — | $0 | 500,000 | SEC↗ |
| Hatzis-Schoch Brent | SEE REMARKS | A Award | 2025-01-30 | 2025-01-31 | 75,000 | — | $0 | 83,400 | SEC↗ |
| Jones Erika | SEE REMARKS | A Award | 2025-01-30 | 2025-01-31 | 75,000 | — | $0 | 85,150 | SEC↗ |
| Buck Elizabeth | CHIEF SCIENTIFIC OFFICER | A Award | 2025-01-30 | 2025-01-31 | 75,000 | — | $0 | 170,192 | SEC↗ |
| Yurasov Sergey | CHIEF MEDICAL OFFICER | A Award | 2025-01-30 | 2025-01-31 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Velleca Mark A. | PRESIDENT & CEO | A Award | 2025-01-30 | 2025-01-31 | 75,000 | — | $0 | 121,522 | SEC↗ |
| Campbell Shannon | Director | A Award | 2024-12-13 | 2024-12-16 | 4,500 | $2.50 | $11.3K | 8,865 | SEC↗ |
| Raman Prakash | Director | A Award | 2024-12-13 | 2024-12-16 | 5,150 | $2.50 | $12.9K | 10,145 | SEC↗ |
| Behbahani Ali | Director | A Award | 2024-12-13 | 2024-12-16 | 5,750 | $2.50 | $14.4K | 63,334 | SEC↗ |
| Raman Prakash | Director | A Award | 2024-09-20 | 2024-09-20 | 2,694 | $4.78 | $12.9K | 4,995 | SEC↗ |
| Campbell Shannon | Director | A Award | 2024-09-20 | 2024-09-20 | 2,354 | $4.78 | $11.3K | 4,365 | SEC↗ |
| Behbahani Ali | Director | A Award | 2024-09-20 | 2024-09-20 | 3,007 | $4.78 | $14.4K | 57,584 | SEC↗ |
| Versant Voyageurs I Parallel, | 10% Owner | S Sale | 2024-08-28 | 2024-08-30 | 221,600 | $6.32 | $1.40M | 3,726,341 | SEC↗ |
| Campbell Shannon | Director | A Award | 2024-06-21 | 2024-06-21 | 2,011 | $4.98 | $10.0K | 2,011 | SEC↗ |
| Raman Prakash | Director | A Award | 2024-06-21 | 2024-06-21 | 2,301 | $4.98 | $11.5K | 2,301 | SEC↗ |
| Behbahani Ali | Director | A Award | 2024-06-21 | 2024-06-21 | 2,887 | $4.98 | $14.4K | 54,577 | SEC↗ |
| Dhingra Kapil | Director | A Award deriv | 2024-06-06 | 2024-06-06 | 30,550 | — | $0 | 30,550 | SEC↗ |
| Campbell Shannon | Director | A Award deriv | 2024-06-06 | 2024-06-06 | 30,550 | — | $0 | 30,550 | SEC↗ |
| Raman Prakash | Director | A Award deriv | 2024-06-06 | 2024-06-06 | 30,550 | — | $0 | 30,550 | SEC↗ |
| Menzel Garry E | Director | A Award deriv | 2024-06-06 | 2024-06-06 | 30,550 | — | $0 | 30,550 | SEC↗ |
| Kulkarni Samarth | Director | A Award deriv | 2024-06-06 | 2024-06-06 | 30,550 | — | $0 | 30,550 | SEC↗ |
| Behbahani Ali | Director | A Award deriv | 2024-06-06 | 2024-06-06 | 30,550 | — | $0 | 30,550 | SEC↗ |
| Raman Prakash | Director | A Award deriv | 2024-04-10 | 2024-04-12 | 61,100 | — | $0 | 61,100 | SEC↗ |
| Campbell Shannon | Director | A Award deriv | 2024-04-10 | 2024-04-12 | 61,100 | — | $0 | 61,100 | SEC↗ |
| DIXON WENDY L | Director | A Award | 2024-03-15 | 2024-04-03 | 3,253 | $4.54 | $14.8K | 38,054 | SEC↗ |
| Behbahani Ali | Director | A Award | 2024-03-15 | 2024-04-03 | 3,166 | $4.54 | $14.4K | 51,690 | SEC↗ |
| Jones Erika | SEE REMARKS | A Award deriv | 2024-02-14 | 2024-02-15 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Velleca Mark A. | PRESIDENT & CEO | A Award deriv | 2024-02-14 | 2024-02-15 | 537,000 | — | $0 | 537,000 | SEC↗ |
| Buck Elizabeth | CHIEF SCIENTIFIC OFFICER | A Award deriv | 2024-02-14 | 2024-02-15 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Yurasov Sergey | CHIEF MEDICAL OFFICER | A Award deriv | 2024-02-14 | 2024-02-15 | 225,000 | — | $0 | 225,000 | SEC↗ |
| Hatzis-Schoch Brent | SEE REMARKS | A Award deriv | 2024-02-14 | 2024-02-15 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Ni Fang | SEE REMARKS | A Award deriv | 2024-02-14 | 2024-02-15 | 200,000 | — | $0 | 200,000 | SEC↗ |
| DIXON WENDY L | Director | A Award | 2023-12-15 | 2023-12-15 | 4,043 | $2.73 | $11.0K | 34,801 | SEC↗ |
| Behbahani Ali | Director | A Award | 2023-12-15 | 2023-12-15 | 4,455 | $2.73 | $12.2K | 48,524 | SEC↗ |
| BIOTECH GROWTH N V | 10% Owner | P Buy | 2023-10-17 | 2023-10-19 | 400,000 | $2.34 | $936.0K | 8,517,839 | SEC↗ |
| Velleca Mark A. | PRESIDENT & CEO | A Award deriv | 2023-09-17 | 2023-09-18 | 1,000,000 | — | $0 | 1,000,000 | SEC↗ |
| DIXON WENDY L | Director | A Award | 2023-09-15 | 2023-09-18 | 2,986 | $3.60 | $10.7K | 30,758 | SEC↗ |
| Velleca Mark A. | PRESIDENT & CEO | A Award | 2023-09-15 | 2023-09-18 | 5,208 | $3.60 | $18.7K | 46,522 | SEC↗ |
| Behbahani Ali | Director | A Award | 2023-09-15 | 2023-09-18 | 3,299 | $3.60 | $11.9K | 44,069 | SEC↗ |
| Behbahani Ali | Director | P Buy | 2023-07-05 | 2023-07-06 | 1,000,000 | $5.00 | $5.00M | 4,448,757 | SEC↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | P Buy | 2023-07-05 | 2023-07-07 | 935,850 | $5.00 | $4.68M | 3,213,828 | SEC↗ |
| BB BIOTECH AG | 10% Owner | P Buy | 2023-06-30 | 2023-07-03 | 1,000,000 | $5.00 | $5.00M | 8,117,839 | SEC↗ |
| Epstein David M. | SEE REMARKS | S Sale | 2023-06-27 | 2023-06-28 | 25,000 | $6.70 | $167.5K | 671,423 | SEC↗ |
| BIOTECH GROWTH N V | 10% Owner | P Buy | 2023-06-27 | 2023-06-29 | 1,740,000 | $5.49 | $9.55M | 7,117,839 | SEC↗ |
| Velleca Mark A. | Director | A Award | 2023-06-16 | 2023-06-16 | 8,929 | $2.10 | $18.8K | 41,314 | SEC↗ |
| DIXON WENDY L | Director | A Award | 2023-06-16 | 2023-06-16 | 5,119 | $2.10 | $10.7K | 27,772 | SEC↗ |
| Behbahani Ali | Director | A Award | 2023-06-16 | 2023-06-16 | 5,655 | $2.10 | $11.9K | 40,770 | SEC↗ |
| Dhingra Kapil | Director | A Award deriv | 2023-05-16 | 2023-05-17 | 16,500 | — | $0 | 16,500 | SEC↗ |
| DIXON WENDY L | Director | A Award deriv | 2023-05-16 | 2023-05-17 | 16,500 | — | $0 | 16,500 | SEC↗ |
| Kulkarni Samarth | Director | A Award deriv | 2023-05-16 | 2023-05-17 | 16,500 | — | $0 | 16,500 | SEC↗ |
| Menzel Garry E | Director | A Award deriv | 2023-05-16 | 2023-05-17 | 16,500 | — | $0 | 16,500 | SEC↗ |
| Velleca Mark A. | Director | A Award deriv | 2023-05-16 | 2023-05-17 | 16,500 | — | $0 | 16,500 | SEC↗ |
| Shah Rajeev M. | Director | A Award deriv | 2023-05-16 | 2023-05-17 | 16,500 | — | $0 | 16,500 | SEC↗ |
| Mayweg Alexander | Director | A Award deriv | 2023-05-16 | 2023-05-17 | 16,500 | — | $0 | 16,500 | SEC↗ |
| Behbahani Ali | Director | A Award deriv | 2023-05-16 | 2023-05-17 | 16,500 | — | $0 | 16,500 | SEC↗ |
| Velleca Mark A. | Director | A Award | 2023-03-16 | 2023-03-20 | 11,228 | $1.67 | $18.8K | 32,385 | SEC↗ |
| DIXON WENDY L | Director | A Award | 2023-03-16 | 2023-03-20 | 6,437 | $1.67 | $10.7K | 22,653 | SEC↗ |
| Behbahani Ali | Director | A Award | 2023-03-16 | 2023-03-20 | 7,111 | $1.67 | $11.9K | 35,115 | SEC↗ |
| Hatzis-Schoch Brent | SEE REMARKS | A Award deriv | 2023-02-13 | 2023-02-15 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Buck Elizabeth | CHIEF SCIENTIFIC OFFICER | A Award deriv | 2023-02-13 | 2023-02-15 | 200,000 | — | $0 | 200,000 | SEC↗ |
| Epstein David M. | SEE REMARKS | A Award deriv | 2023-02-13 | 2023-02-15 | 420,000 | — | $0 | 420,000 | SEC↗ |
| Jones Erika | SEE REMARKS | A Award deriv | 2023-02-13 | 2023-02-15 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Ni Fang | SEE REMARKS | A Award deriv | 2023-02-13 | 2023-02-15 | 400,000 | — | $0 | 400,000 | SEC↗ |
| Yurasov Sergey | CHIEF MEDICAL OFFICER | A Award deriv | 2023-02-13 | 2023-02-15 | 250,000 | — | $0 | 250,000 | SEC↗ |
| Jones Erika | SEE REMARKS | A Award | 2023-02-13 | 2023-02-15 | 5,075 | — | $0 | 10,150 | SEC↗ |
| Ni Fang | SEE REMARKS | P Buy | 2022-12-22 | 2022-12-23 | 36,363 | $1.28 | $46.5K | 125,389 | SEC↗ |
| Ni Fang | SEE REMARKS | P Buy | 2022-12-21 | 2022-12-23 | 20,000 | $1.29 | $25.8K | 89,026 | SEC↗ |
| INGRAM ROBERT ALEXANDER | Other | A Award | 2022-12-16 | 2022-12-19 | 9,375 | $1.50 | $14.1K | 42,854 | SEC↗ |
| DIXON WENDY L | Director | A Award | 2022-12-16 | 2022-12-19 | 7,167 | $1.50 | $10.8K | 16,216 | SEC↗ |
| Velleca Mark A. | Director | A Award | 2022-12-16 | 2022-12-19 | 8,424 | $1.50 | $12.6K | 21,157 | SEC↗ |
| Behbahani Ali | Director | A Award | 2022-12-16 | 2022-12-19 | 7,917 | $1.50 | $11.9K | 28,004 | SEC↗ |
| BIOTECH GROWTH N V | 10% Owner | P Buy | 2022-10-31 | 2022-11-02 | 99,801 | $2.25 | $224.6K | 5,377,839 | SEC↗ |
| BB BIOTECH AG | 10% Owner | P Buy | 2022-10-28 | 2022-10-31 | 172,974 | $2.18 | $377.1K | 5,278,038 | SEC↗ |
| BB BIOTECH AG | 10% Owner | P Buy | 2022-10-27 | 2022-10-31 | 191,678 | $1.87 | $358.4K | 5,105,064 | SEC↗ |
| BB BIOTECH AG | 10% Owner | P Buy | 2022-10-21 | 2022-10-25 | 87,850 | $1.51 | $132.7K | 4,913,386 | SEC↗ |
| BB BIOTECH AG | 10% Owner | P Buy | 2022-10-20 | 2022-10-21 | 53,734 | $1.42 | $76.3K | 4,825,536 | SEC↗ |
| BB BIOTECH AG | 10% Owner | P Buy | 2022-10-19 | 2022-10-21 | 77,689 | $1.32 | $102.5K | 4,771,802 | SEC↗ |
| INGRAM ROBERT ALEXANDER | Director | A Award | 2022-09-16 | 2022-09-19 | 6,584 | $2.62 | $17.3K | 33,479 | SEC↗ |
| Velleca Mark A. | Director | A Award | 2022-09-16 | 2022-09-19 | 4,294 | $2.62 | $11.3K | 12,733 | SEC↗ |
| DIXON WENDY L | Director | A Award | 2022-09-16 | 2022-09-19 | 4,103 | $2.62 | $10.7K | 9,049 | SEC↗ |
| Behbahani Ali | Director | A Award | 2022-09-16 | 2022-09-19 | 4,532 | $2.62 | $11.9K | 20,087 | SEC↗ |
| Ni Fang | SEE REMARKS | P Buy | 2022-06-29 | 2022-06-30 | 25,000 | $2.44 | $61.0K | 69,026 | SEC↗ |
| INGRAM ROBERT ALEXANDER | Director | A Award | 2022-06-17 | 2022-06-17 | 8,498 | $2.03 | $17.3K | 26,895 | SEC↗ |
| DIXON WENDY L | Director | A Award | 2022-06-17 | 2022-06-17 | 4,060 | $2.03 | $8.2K | 4,060 | SEC↗ |
| Velleca Mark A. | Director | A Award | 2022-06-17 | 2022-06-17 | 5,542 | $2.03 | $11.3K | 8,439 | SEC↗ |
| Behbahani Ali | Director | A Award | 2022-06-17 | 2022-06-17 | 5,850 | $2.03 | $11.9K | 15,555 | SEC↗ |
| DIXON WENDY L | Director | A Award | 2022-06-17 | 2022-06-30 | 4,946 | $2.03 | $10.0K | 4,946 | SEC↗ |
| DIXON WENDY L | Director | A Award deriv | 2022-06-10 | 2022-06-13 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Kulkarni Samarth | Director | A Award deriv | 2022-06-10 | 2022-06-13 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Menzel Garry E | Director | A Award deriv | 2022-06-10 | 2022-06-13 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Dhingra Kapil | Director | A Award deriv | 2022-06-10 | 2022-06-13 | 15,000 | — | $0 | 15,000 | SEC↗ |
| INGRAM ROBERT ALEXANDER | Director | A Award deriv | 2022-06-10 | 2022-06-13 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Shah Rajeev M. | Director | A Award deriv | 2022-06-10 | 2022-06-13 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Velleca Mark A. | Director | A Award deriv | 2022-06-10 | 2022-06-13 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Behbahani Ali | Director | A Award deriv | 2022-06-10 | 2022-06-13 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Mayweg Alexander | Director | A Award deriv | 2022-06-10 | 2022-06-13 | 15,000 | — | $0 | 15,000 | SEC↗ |
| BIOTECH GROWTH N V | 10% Owner | P Buy | 2022-04-28 | 2022-04-29 | 255,711 | $2.57 | $657.2K | 4,694,113 | SEC↗ |
| BIOTECH GROWTH N V | 10% Owner | P Buy | 2022-04-27 | 2022-04-29 | 150,000 | $2.66 | $399.0K | 4,438,402 | SEC↗ |
| BIOTECH GROWTH N V | 10% Owner | P Buy | 2022-04-19 | 2022-04-20 | 150,000 | $3.24 | $486.0K | 4,288,402 | SEC↗ |
| BIOTECH GROWTH N V | 10% Owner | P Buy | 2022-04-18 | 2022-04-20 | 150,000 | $3.29 | $493.5K | 4,138,402 | SEC↗ |
| BIOTECH GROWTH N V | 10% Owner | P Buy | 2022-04-13 | 2022-04-14 | 102,556 | $3.57 | $366.1K | 3,988,402 | SEC↗ |
| BIOTECH GROWTH N V | 10% Owner | P Buy | 2022-04-12 | 2022-04-14 | 150,000 | $3.42 | $513.0K | 3,885,846 | SEC↗ |
| DIXON WENDY L | Director | A Award deriv | 2022-04-06 | 2022-04-07 | 30,000 | — | $0 | 30,000 | SEC↗ |
| INGRAM ROBERT ALEXANDER | Director | A Award | 2022-03-18 | 2022-03-18 | 5,795 | $3.02 | $17.5K | 18,397 | SEC↗ |
| Velleca Mark A. | Director | A Award | 2022-03-18 | 2022-03-18 | 2,897 | $3.02 | $8.7K | 2,897 | SEC↗ |
| Behbahani Ali | Director | A Award | 2022-03-18 | 2022-03-18 | 4,346 | $3.02 | $13.1K | 9,705 | SEC↗ |
| Ni Fang | SEE REMARKS | A Award deriv | 2022-02-15 | 2022-02-17 | 100,000 | — | $0 | 100,000 | SEC↗ |
| Buck Elizabeth | CHIEF SCIENTIFIC OFFICER | A Award deriv | 2022-02-15 | 2022-02-17 | 90,000 | — | $0 | 90,000 | SEC↗ |
| Jones Erika | SEE REMARKS | A Award deriv | 2022-02-15 | 2022-02-17 | 20,300 | — | $0 | 20,300 | SEC↗ |
| Epstein David M. | SEE REMARKS | A Award deriv | 2022-02-15 | 2022-02-17 | 300,000 | — | $0 | 300,000 | SEC↗ |
| Hatzis-Schoch Brent | SEE REMARKS | A Award deriv | 2022-02-15 | 2022-02-17 | 90,000 | — | $0 | 90,000 | SEC↗ |
| Jones Erika | SEE REMARKS | A Award | 2022-02-15 | 2022-02-17 | 5,075 | — | $0 | 5,075 | SEC↗ |
| INGRAM ROBERT ALEXANDER | Director | A Award | 2021-12-17 | 2021-12-17 | 3,296 | $5.31 | $17.5K | 12,602 | SEC↗ |
| Behbahani Ali | Director | A Award | 2021-12-17 | 2021-12-17 | 2,472 | $5.31 | $13.1K | 5,359 | SEC↗ |
| INGRAM ROBERT ALEXANDER | Director | A Award | 2021-09-17 | 2021-09-23 | 1,869 | $9.90 | $18.5K | 9,306 | SEC↗ |
| Behbahani Ali | Director | A Award | 2021-09-17 | 2021-09-23 | 1,326 | $9.90 | $13.1K | 2,887 | SEC↗ |
| Velleca Mark A. | Director | A Award deriv | 2021-08-09 | 2021-08-11 | 30,000 | — | $0 | 30,000 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | A Award deriv | 2021-06-18 | 2021-06-22 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Dhingra Kapil | Director | A Award deriv | 2021-06-18 | 2021-06-22 | 15,000 | — | $0 | 15,000 | SEC↗ |
| INGRAM ROBERT ALEXANDER | Director | A Award deriv | 2021-06-18 | 2021-06-22 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Kulkarni Samarth | Director | A Award deriv | 2021-06-18 | 2021-06-22 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Mayweg Alexander | Director | A Award deriv | 2021-06-18 | 2021-06-22 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Menzel Garry E | Director | A Award deriv | 2021-06-18 | 2021-06-22 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Shah Rajeev M. | Director | A Award deriv | 2021-06-18 | 2021-06-22 | 15,000 | — | $0 | 15,000 | SEC↗ |
| Behbahani Ali | Director | A Award deriv | 2021-06-18 | 2021-06-22 | 15,000 | — | $0 | 15,000 | SEC↗ |
| INGRAM ROBERT ALEXANDER | Director | A Award | 2021-06-18 | 2021-06-22 | 1,255 | $12.95 | $16.3K | 7,437 | SEC↗ |
| Behbahani Ali | Director | A Award | 2021-06-18 | 2021-06-22 | 1,014 | $12.95 | $13.1K | 1,561 | SEC↗ |
| Shah Rajeev M. | Director | J Other | 2021-05-20 | 2021-05-21 | 443 | $24.01 | $10.6K | 0 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | M Exercise deriv | 2021-05-12 | 2021-05-13 | 4,078 | — | $0 | 160,474 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | S Sale | 2021-05-12 | 2021-05-13 | 351 | $28.20 | $9.9K | 8,400 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | S Sale | 2021-05-12 | 2021-05-13 | 2,566 | $27.90 | $71.6K | 8,751 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | S Sale | 2021-05-12 | 2021-05-13 | 1,161 | $26.11 | $30.3K | 11,317 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | M Exercise | 2021-05-12 | 2021-05-13 | 4,078 | $3.20 | $13.0K | 12,478 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | M Exercise deriv | 2021-05-03 | 2021-05-05 | 2,500 | — | $0 | 163,609 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | S Sale | 2021-05-03 | 2021-05-05 | 2,500 | $26.64 | $66.6K | 3,200 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | M Exercise | 2021-05-03 | 2021-05-05 | 2,500 | $10.86 | $27.1K | 5,700 | SEC↗ |
| Kulkarni Samarth | Director | A Award deriv | 2021-04-20 | 2021-04-23 | 14,921 | — | $0 | 14,921 | SEC↗ |
| Menzel Garry E | Director | A Award deriv | 2021-04-20 | 2021-04-23 | 14,921 | — | $0 | 14,921 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | M Exercise deriv | 2021-04-12 | 2021-04-13 | 179,915 | — | $0 | 164,552 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | S Sale | 2021-04-12 | 2021-04-13 | 4,078 | $25.00 | $102.0K | 8,400 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | M Exercise | 2021-04-12 | 2021-04-13 | 4,078 | $3.20 | $13.0K | 12,478 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | M Exercise deriv | 2021-04-05 | 2021-04-07 | 2,500 | — | $0 | 166,109 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | M Exercise | 2021-04-05 | 2021-04-07 | 2,500 | $10.86 | $27.1K | 5,700 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | S Sale | 2021-04-05 | 2021-04-07 | 2,500 | $25.54 | $63.9K | 3,200 | SEC↗ |
| Shah Rajeev M. | Director | J Other | 2021-04-01 | 2021-04-05 | 353,814 | $24.26 | $8.58M | 2,277,978 | SEC↗ |
| INGRAM ROBERT ALEXANDER | Director | A Award | 2021-03-18 | 2021-03-22 | 677 | $24.01 | $16.3K | 6,182 | SEC↗ |
| Shah Rajeev M. | Director | A Award | 2021-03-18 | 2021-03-22 | 443 | $24.01 | $10.6K | 443 | SEC↗ |
| Behbahani Ali | Director | A Award | 2021-03-18 | 2021-03-22 | 547 | $24.01 | $13.1K | 547 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | M Exercise deriv | 2021-03-12 | 2021-03-16 | 4,078 | — | $0 | 168,630 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | S Sale | 2021-03-12 | 2021-03-16 | 4,078 | $26.36 | $107.5K | 8,400 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | M Exercise | 2021-03-12 | 2021-03-16 | 4,078 | $3.20 | $13.0K | 12,478 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | M Exercise deriv | 2021-03-03 | 2021-03-04 | 2,500 | — | $0 | 168,609 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | S Sale | 2021-03-03 | 2021-03-04 | 884 | $26.57 | $23.5K | 3,200 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | M Exercise | 2021-03-03 | 2021-03-04 | 2,500 | $10.86 | $27.1K | 5,700 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | S Sale | 2021-03-03 | 2021-03-04 | 1,616 | $25.85 | $41.8K | 4,084 | SEC↗ |
| Epstein David M. | See Remarks | A Award deriv | 2021-02-17 | 2021-02-19 | 225,000 | — | $0 | 225,000 | SEC↗ |
| Leggett Thomas | Chief Financial Officer | A Award deriv | 2021-02-17 | 2021-02-19 | 75,000 | — | $0 | 75,000 | SEC↗ |
| HUMPHREY RACHEL | Chief Medical Officer | A Award deriv | 2021-02-17 | 2021-02-19 | 60,000 | — | $0 | 60,000 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | A Award deriv | 2021-02-17 | 2021-02-19 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | A Award deriv | 2021-02-17 | 2021-02-19 | 75,000 | — | $0 | 75,000 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | M Exercise deriv | 2021-02-12 | 2021-02-12 | 4,078 | — | $0 | 172,708 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | S Sale | 2021-02-12 | 2021-02-12 | 307 | $27.66 | $8.5K | 8,400 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | S Sale | 2021-02-12 | 2021-02-12 | 3,771 | $27.19 | $102.5K | 8,707 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | M Exercise | 2021-02-12 | 2021-02-12 | 4,078 | $3.20 | $13.0K | 12,478 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | M Exercise deriv | 2021-02-03 | 2021-02-04 | 2,500 | — | $0 | 171,109 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | M Exercise | 2021-02-03 | 2021-02-04 | 2,500 | $10.86 | $27.1K | 5,700 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | S Sale | 2021-02-03 | 2021-02-04 | 2,500 | $25.35 | $63.4K | 3,200 | SEC↗ |
| Dhingra Kapil | Director | A Award deriv | 2021-01-19 | 2021-01-22 | 29,842 | — | $0 | 29,842 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | M Exercise deriv | 2021-01-12 | 2021-01-14 | 7,500 | — | $0 | 71,251 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | M Exercise deriv | 2021-01-12 | 2021-01-14 | 4,078 | — | $0 | 176,786 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | S Sale | 2021-01-12 | 2021-01-14 | 1,669 | $30.50 | $50.9K | 16,261 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | S Sale | 2021-01-12 | 2021-01-14 | 100 | $34.13 | $3.4K | 15,911 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | S Sale | 2021-01-12 | 2021-01-14 | 103 | $32.50 | $3.3K | 16,011 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | S Sale | 2021-01-12 | 2021-01-14 | 147 | $31.91 | $4.7K | 16,114 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | S Sale | 2021-01-12 | 2021-01-14 | 7,511 | $36.00 | $270.4K | 8,400 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | S Sale | 2021-01-12 | 2021-01-14 | 2,048 | $29.92 | $61.3K | 17,930 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | M Exercise | 2021-01-12 | 2021-01-14 | 7,500 | $10.86 | $81.5K | 19,978 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | M Exercise | 2021-01-12 | 2021-01-14 | 4,078 | $3.20 | $13.0K | 12,478 | SEC↗ |
| Leggett Thomas | Chief Financial Officer | M Exercise deriv | 2021-01-08 | 2021-01-11 | 3,000 | — | $0 | 218,171 | SEC↗ |
| Leggett Thomas | Chief Financial Officer | S Sale | 2021-01-08 | 2021-01-11 | 3,000 | $33.94 | $101.8K | 0 | SEC↗ |
| Leggett Thomas | Chief Financial Officer | M Exercise | 2021-01-08 | 2021-01-11 | 3,000 | $10.86 | $32.6K | 3,000 | SEC↗ |
| Epstein David M. | See Remarks | M Exercise deriv | 2021-01-04 | 2021-01-06 | 3,000 | — | $0 | 230,116 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | M Exercise deriv | 2021-01-04 | 2021-01-06 | 2,500 | — | $0 | 173,609 | SEC↗ |
| Epstein David M. | See Remarks | S Sale | 2021-01-04 | 2021-01-06 | 9,985 | $30.99 | $309.4K | 698,438 | SEC↗ |
| Epstein David M. | See Remarks | S Sale | 2021-01-04 | 2021-01-06 | 2,015 | $31.80 | $64.1K | 696,423 | SEC↗ |
| Epstein David M. | See Remarks | M Exercise | 2021-01-04 | 2021-01-06 | 3,000 | $6.42 | $19.3K | 708,423 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | S Sale | 2021-01-04 | 2021-01-06 | 1,963 | $31.31 | $61.5K | 3,737 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | S Sale | 2021-01-04 | 2021-01-06 | 537 | $31.78 | $17.1K | 3,200 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | M Exercise | 2021-01-04 | 2021-01-06 | 2,500 | $10.86 | $27.1K | 5,700 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | M Exercise deriv | 2020-12-28 | 2020-12-29 | 5,400 | — | $0 | 180,864 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | M Exercise | 2020-12-28 | 2020-12-29 | 5,400 | $3.20 | $17.3K | 8,400 | SEC↗ |
| Epstein David M. | See Remarks | M Exercise deriv | 2020-12-15 | 2020-12-16 | 2,500 | — | $0 | 233,116 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | M Exercise deriv | 2020-12-15 | 2020-12-16 | 3,200 | — | $0 | 176,109 | SEC↗ |
| Epstein David M. | See Remarks | M Exercise | 2020-12-15 | 2020-12-16 | 2,500 | $6.42 | $16.1K | 705,423 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | M Exercise | 2020-12-15 | 2020-12-16 | 3,200 | $10.86 | $34.8K | 3,200 | SEC↗ |
| INGRAM ROBERT ALEXANDER | Director | A Award | 2020-12-15 | 2020-12-16 | 505 | $34.29 | $17.3K | 5,505 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | M Exercise deriv | 2020-12-14 | 2020-12-16 | 4,078 | — | $0 | 186,264 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-12-14 | 2020-12-16 | 11 | — | $0 | 21,851 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-12-14 | 2020-12-16 | 307 | — | $0 | 0 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-12-14 | 2020-12-16 | 307 | — | $0 | 307 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-12-14 | 2020-12-16 | 310 | — | $0 | 0 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-12-14 | 2020-12-16 | 310 | — | $0 | 310 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-12-14 | 2020-12-16 | 20,784 | — | $0 | 822,140 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | J Other | 2020-12-14 | 2020-12-16 | 310 | — | $0 | 0 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | J Other | 2020-12-14 | 2020-12-16 | 307 | — | $0 | 307 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | J Other | 2020-12-14 | 2020-12-16 | 307 | — | $0 | 0 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | J Other | 2020-12-14 | 2020-12-16 | 20,784 | — | $0 | 822,140 | SEC↗ |
| Versant Vantage I, L.P. | 10% Owner | J Other | 2020-12-14 | 2020-12-16 | 310 | — | $0 | 310 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | M Exercise | 2020-12-14 | 2020-12-16 | 4,078 | $3.20 | $13.0K | 7,078 | SEC↗ |
| Hatzis-Schoch Brent | See Remarks | S Sale | 2020-12-14 | 2020-12-16 | 4,078 | $34.95 | $142.5K | 3,000 | SEC↗ |
| Leggett Thomas | Chief Financial Officer | M Exercise deriv | 2020-12-08 | 2020-12-10 | 3,000 | — | $0 | 221,171 | SEC↗ |
| Leggett Thomas | Chief Financial Officer | M Exercise | 2020-12-08 | 2020-12-10 | 3,000 | $10.86 | $32.6K | 3,000 | SEC↗ |
| Leggett Thomas | Chief Financial Officer | S Sale | 2020-12-08 | 2020-12-10 | 1,941 | $34.05 | $66.1K | 0 | SEC↗ |
| Leggett Thomas | Chief Financial Officer | S Sale | 2020-12-08 | 2020-12-10 | 1,059 | $33.27 | $35.2K | 1,941 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | M Exercise deriv | 2020-12-03 | 2020-12-04 | 2,500 | — | $0 | 179,309 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | S Sale | 2020-12-03 | 2020-12-04 | 2,500 | $32.42 | $81.0K | 0 | SEC↗ |
| Roberts Christopher D. | Chief Scientific Officer | M Exercise | 2020-12-03 | 2020-12-04 | 2,500 | $10.86 | $27.1K | 2,500 | SEC↗ |
| Epstein David M. | See Remarks | M Exercise deriv | 2020-12-01 | 2020-12-03 | 3,000 | — | $0 | 235,616 | SEC↗ |
| Epstein David M. | See Remarks | S Sale | 2020-12-01 | 2020-12-03 | 10,923 | $32.64 | $356.5K | 704,000 | SEC↗ |
| Epstein David M. | See Remarks | S Sale | 2020-12-01 | 2020-12-03 | 1,077 | $33.45 | $36.0K | 702,923 | SEC↗ |
| Epstein David M. | See Remarks | M Exercise | 2020-12-01 | 2020-12-03 | 3,000 | $6.42 | $19.3K | 714,923 | SEC↗ |
| Versant Voyageurs I Parallel, | 10% Owner | S Sale | 2020-11-30 | 2020-12-01 | 200 | $34.16 | $6.8K | 874,099 | SEC↗ |
| Versant Voyageurs I Parallel, | 10% Owner | J Other | 2020-11-30 | 2020-12-01 | 31,175 | — | $0 | 842,924 | SEC↗ |
| Versant Voyageurs I Parallel, | 10% Owner | J Other | 2020-11-30 | 2020-12-01 | 463 | — | $0 | 0 | SEC↗ |
| Versant Voyageurs I Parallel, | 10% Owner | J Other | 2020-11-30 | 2020-12-01 | 463 | — | $0 | 463 | SEC↗ |
| Versant Voyageurs I Parallel, | 10% Owner | J Other | 2020-11-30 | 2020-12-01 | 467 | — | $0 | 0 | SEC↗ |
| Versant Voyageurs I Parallel, | 10% Owner | J Other | 2020-11-30 | 2020-12-01 | 467 | — | $0 | 467 | SEC↗ |
| Versant Voyageurs I Parallel, | 10% Owner | S Sale | 2020-11-30 | 2020-12-01 | 10,193 | $33.13 | $337.7K | 874,299 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-30 | 2020-12-01 | 15 | — | $0 | 21,840 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-30 | 2020-12-01 | 463 | — | $0 | 0 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-30 | 2020-12-01 | 463 | — | $0 | 463 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-30 | 2020-12-01 | 467 | — | $0 | 0 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-30 | 2020-12-01 | 467 | — | $0 | 467 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-30 | 2020-12-01 | 31,175 | — | $0 | 842,924 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | S Sale | 2020-11-30 | 2020-12-01 | 200 | $34.16 | $6.8K | 874,099 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | S Sale | 2020-11-30 | 2020-12-01 | 10,193 | $33.13 | $337.7K | 874,299 | SEC↗ |
| Versant Voyageurs I Parallel, | 10% Owner | J Other | 2020-11-27 | 2020-12-01 | 6,797 | — | $0 | 6,797 | SEC↗ |
| Versant Voyageurs I Parallel, | 10% Owner | J Other | 2020-11-27 | 2020-12-01 | 7,880 | — | $0 | 0 | SEC↗ |
| Versant Voyageurs I Parallel, | 10% Owner | J Other | 2020-11-27 | 2020-12-01 | 7,880 | — | $0 | 7,880 | SEC↗ |
| Versant Voyageurs I Parallel, | 10% Owner | J Other | 2020-11-27 | 2020-12-01 | 394,000 | — | $0 | 3,947,941 | SEC↗ |
| Versant Voyageurs I Parallel, | 10% Owner | J Other | 2020-11-27 | 2020-12-01 | 6,797 | — | $0 | 0 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-27 | 2020-12-01 | 6,797 | — | $0 | 6,797 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-27 | 2020-12-01 | 7,880 | — | $0 | 0 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-27 | 2020-12-01 | 7,880 | — | $0 | 7,880 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-27 | 2020-12-01 | 394,000 | — | $0 | 3,947,941 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-27 | 2020-12-01 | 2,256 | — | $0 | 21,825 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-27 | 2020-12-01 | 6,797 | — | $0 | 0 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-23 | 2020-11-25 | 9,533 | — | $0 | 9,533 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-23 | 2020-11-25 | 476,659 | — | $0 | 4,341,941 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-23 | 2020-11-25 | 9,533 | — | $0 | 0 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-23 | 2020-11-25 | 1,164 | — | $0 | 19,569 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-23 | 2020-11-25 | 3,316 | — | $0 | 0 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-23 | 2020-11-25 | 2,488 | — | $0 | 3,316 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-23 | 2020-11-25 | 46,121 | — | $0 | 380,942 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-23 | 2020-11-25 | 828 | — | $0 | 828 | SEC↗ |
| Bolzon Bradley J PhD | Director, 10% Owner | J Other | 2020-11-23 | 2020-11-25 | 154,671 | — | $0 | 1,277,541 | SEC↗ |